{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:43:32Z","timestamp":1785404612245,"version":"3.56.0"},"reference-count":44,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1136\/bjophthalmol-2012-303026","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T00:51:09Z","timestamp":1368751869000},"page":"1510-1515","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":51,"title":["Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension"],"prefix":"10.1136","volume":"97","author":[{"given":"Anastasios G P","family":"Konstas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini C","family":"Voudouragkaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Paschalinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Floriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Bettina","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2012-303026-1","first-page":"1806","article-title":"Effects of benzalconium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells","volume":"17","author":"Ammar","year":"2011","journal-title":"Mol Vis"},{"key":"key-10.1136\/bjophthalmol-2012-303026-2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"key-10.1136\/bjophthalmol-2012-303026-3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","article-title":"Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies","volume":"106","author":"Baudouin","year":"1999","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-303026-4","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archopht.1990.01070130045027","article-title":"The influence of prior therapy on the success of trabeculectomy","volume":"108","author":"Lavin","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jop.2009.0066","article-title":"A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost","volume":"26","author":"Traverso","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","article-title":"Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2147\/OPTH.S13720","article-title":"Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension","volume":"4","author":"Schnober","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"Suppl 242","key":"key-10.1136\/bjophthalmol-2012-303026-10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-3768.2008.01381.x","article-title":"Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis","volume":"86","author":"Hamacher","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ajo.2011.11.008","article-title":"Randomized clinical trial on the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"153","author":"Chabi","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007995.2010.492030","article-title":"IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma","volume":"26","author":"Hommer","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key-10.1136\/bjophthalmol-2012-303026-14","first-page":"623","article-title":"Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost","volume":"5","author":"Hommer","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12325-011-0038-9","article-title":"Preservative-free Tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension","volume":"28","author":"Erb","year":"2011","journal-title":"Adv Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14740338.2012.690734","article-title":"Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on na\u00efve ocular hypertension or glaucoma patients","volume":"11","author":"Rossi","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"key-10.1136\/bjophthalmol-2012-303026-17","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/804730","article-title":"A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to non-preserved Tafluprost in glaucoma patients","author":"Ranno","year":"2012","journal-title":"Scientific World J"},{"key":"key-10.1136\/bjophthalmol-2012-303026-18","doi-asserted-by":"crossref","DOI":"10.1002\/0470854596","volume-title":"Cross-over trials in clinical research","author":"Senn","year":"2002","edition":"2"},{"key":"key-10.1136\/bjophthalmol-2012-303026-19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","article-title":"Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug","volume":"78","author":"Takagi","year":"2004","journal-title":"Exp Eye Res"},{"key":"key-10.1136\/bjophthalmol-2012-303026-20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/OPTH.S6368","article-title":"Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension","volume":"4","author":"Aihara","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12325-011-0055-8","article-title":"Tafluprost: a novel prostaglandin analog for treatment of glaucoma","volume":"28","author":"Pantcheva","year":"2011","journal-title":"Adv Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/jop.2006.0061","article-title":"A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males","volume":"23","author":"Sutton","year":"2007","journal-title":"J Ocul Pharm Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5414\/CPP46400","article-title":"Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers","volume":"46","author":"Sutton","year":"2008","journal-title":"Int J Clin Pharm Ther"},{"issue":"Suppl 242","key":"key-10.1136\/bjophthalmol-2012-303026-24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1755-3768.2008.01380.x","article-title":"Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers","volume":"86","author":"Uusitalo","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-010-0828-7","article-title":"Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects","volume":"54","author":"Mochizuki","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10384-012-0155-2","article-title":"Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects","volume":"56","author":"Kawaguchi","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-27","unstructured":"SAFLUTAN (tafluprost), Summary of product characteristics, date of revision: 16 March 2011. http:\/\/www.medicines.org.uk\/EMC\/medicine\/22237\/SPC\/SAFLUTAN+15+micrograms+ml+eye+drops%2c+solution%2c+single-dose+container\/ (accessed 18 Dec 2012)."},{"key":"key-10.1136\/bjophthalmol-2012-303026-28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bjophthalmol-2011-301015","article-title":"Spanish multicenter tafluprost tolerability study","volume":"96","author":"Milla","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S28104","article-title":"Effects of preservative-free tafluprost on tear film osmolarity, tolerability and intraocular pressure in previously treated patients with open-angle glaucoma","volume":"6","author":"Januleviciene","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","article-title":"Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines","volume":"115","author":"Stewart","year":"2008","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-303026-31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00061198-200004000-00002","article-title":"Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma","volume":"9","author":"Asrani","year":"2000","journal-title":"J Glaucoma"},{"key":"key-10.1136\/bjophthalmol-2012-303026-32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.124.6.793","article-title":"Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma","volume":"124","author":"Barkana","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/jop.2011.0081","article-title":"Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma","volume":"28","author":"Konstas","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14656566.2012.662485","article-title":"Overview of the BAK-free travoprost\/timolol fixed combination","volume":"13","author":"Konstas","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.1136\/bjophthalmol-2012-303026-35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.survophthal.2012.05.003","article-title":"24-hour intraocular pressure and ocular perfusion pressure in glaucoma","volume":"58","author":"Quaranta","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"key":"key-10.1136\/bjophthalmol-2012-303026-37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/108076803762718088","article-title":"Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension","volume":"19","author":"Feldman","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-38","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0149-2918(03)80074-7","article-title":"Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study","volume":"25","author":"Reardon","year":"2003","journal-title":"Clin Ther"},{"key":"key-10.1136\/bjophthalmol-2012-303026-39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5301\/ejo.5000181","article-title":"Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension","volume":"23","author":"Baudouin","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1477-7525-1-75","article-title":"Vision related quality of life and topical glaucoma treatment side effects","volume":"1","author":"Nordmann","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"key-10.1136\/bjophthalmol-2012-303026-41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure- lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2012-303026-43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-303026-44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2012-303026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:44:01Z","timestamp":1601109841000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2012-303026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,11,8]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/bjophthalmol-2012-303026"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2012-303026","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}